0TDF Stoklara Genel Bakış Roche Holding AG, Avrupa, Kuzey Amerika, Latin Amerika, Asya, Afrika, Avustralya ve Yeni Zelanda'da ilaç ve diagnostik alanlarında faaliyet göstermektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Roche Holding AG Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Roche Holding Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı CHF 40.86 52 Haftanın En Yüksek Seviyesi CHF 41.85 52 Haftanın En Düşük Seviyesi CHF 29.27 Beta 0.18 1 Aylık Değişim 12.31% 3 Aylık Değişim 15.49% 1 Yıllık Değişim 23.78% 3 Yıllık Değişim -12.46% 5 Yıllık Değişim -6.42% Halka arzdan bu yana değişim 32.28%
Son Haberler & Güncellemeler
Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(K) Clearance Feb 15
Legacy Pharma Inc. SEZC acquired InterMune, Inc. from Roche Holding AG (SWX:ROG). Feb 07
Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness Feb 05
Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTU Feb 01 Roche Holding AG Reports Earnings Guidance for the Year 2025
Roche Announces Executive and Committee Changes Jan 29 Daha fazla güncelleme görün
Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(K) Clearance Feb 15
Legacy Pharma Inc. SEZC acquired InterMune, Inc. from Roche Holding AG (SWX:ROG). Feb 07
Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness Feb 05
Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTU Feb 01 Roche Holding AG Reports Earnings Guidance for the Year 2025
Roche Announces Executive and Committee Changes Jan 29 Roche's Itovebi Demonstrates Statically Significant and clinically meaningful Overall Survival Benefit in A Certain Type of HR-Positive Advanced Breast Cancer
Roche Receives FDA Clearance with CLIA Waiver for Cobas® liat Molecular Tests to Diagnose Sexually Transmitted Infections At the Point of Care Jan 22
Roche Receives FDA Clearance For VENTANA DP 600 Slide Scanner In Digital Pathology Jan 09
Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025 Jan 02
Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions Dec 13
New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma Dec 10
Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma Dec 09
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Dec 05
Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA Nov 25
Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024 Nov 05
Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease Nov 02 Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials
Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study Oct 14
FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation Oct 11 Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG). Oct 02
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis Sep 14
FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Sep 13 Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis Sep 04
Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH Aug 27
European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO) Jul 30
Roche Holding AG Raises Earnings Guidance for the Year 2024 Jul 25
BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche Jul 23 New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD) Jul 09
Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer Jul 04
Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024 Jun 26
Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis Jun 25
Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma Jun 20 Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma Jun 17
Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant May 31
Roche Announces Management and Board Committee Changes May 28
Roche Receives FDA Device Designation for Blood Test Measuring Lp(a) May 25
Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity May 18
Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer May 16
Roche Holding AG Provides Earnings Guidance for the Year 2024 Apr 24 FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer Apr 20
Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab) Apr 17
Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis Apr 12
Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors Mar 27 Roche Holding AG, Annual General Meeting, Mar 12, 2024 Mar 13
Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension Mar 05
Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies Feb 17
Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need Feb 12 Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO) Feb 02
Roche Holding AG Proposes Dividend
Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders. Jan 30
Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders. Jan 29
European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types Jan 16
Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024 Dec 20
Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition Dec 12
Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A Dec 11 Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion. Dec 04
Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection Nov 29
Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection Nov 28
Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List Nov 18 Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types Nov 17
Hissedar Getirileri 0TDF GB Pharmaceuticals GB Pazar 7D 3.5% -0.4% -0.1% 1Y 23.8% 6.4% 10.6%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 0TDF geçen yıl % 6.4 oranında getiri sağlayan UK Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: 0TDF geçen yıl % 10.6 oranında getiri sağlayan UK Piyasasını aştı.
Fiyat Oynaklığı Is 0TDF's price volatile compared to industry and market? 0TDF volatility 0TDF Average Weekly Movement 4.2% Pharmaceuticals Industry Average Movement 7.8% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
İstikrarlı Hisse Senedi Fiyatı: 0TDF son 3 ayda UK piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 0TDF 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Kuruldu Çalışanlar CEO Web sitesi 1896 103,249 Thomas Schinecker www.roche.com
Roche Holding AG, Avrupa, Kuzey Amerika, Latin Amerika, Asya, Afrika, Avustralya ve Yeni Zelanda'da ilaç ve diagnostik alanlarında faaliyet göstermektedir. Şirket, anemi, kan ve solid tümörler, dermatoloji, hemofili, enflamatuar ve otoimmün, nörolojik bozukluklar, oftalmoloji, solunum bozuklukları ve transplantasyon terapötik alanlarında ilaç çözümleri sunmaktadır. Ayrıca kanser, diyabet, Covid-19, hepatit, insan papilloma virüsü ve diğerleri gibi çeşitli hastalıkların teşhisi için in vitro testler; teşhis cihazları ve dijital sağlık çözümleri sunmaktadır.
Daha fazla göster Roche Holding AG Temel Bilgiler Özeti Roche Holding'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 0TDF temel i̇stati̇sti̇kler Piyasa değeri US$262.44b Kazançlar(TTM ) US$9.19b Gelir(TTM ) US$69.26b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 0TDF gelir tablosu (TTM ) Gelir CHF 62.40b Gelir Maliyeti CHF 15.73b Brüt Kâr CHF 46.66b Diğer Giderler CHF 38.39b Kazançlar CHF 8.28b
Son Raporlanan Kazançlar
Dec 31, 2024
Sonraki Kazanç Tarihi
Jul 24, 2025
Hisse başına kazanç (EPS) 10.41 Brüt Marj 74.79% Net Kâr Marjı 13.27% Borç/Özkaynak Oranı 95.9%
0TDF uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün Temettüler
3.3% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/02/18 13:47 Gün Sonu Hisse Fiyatı 2025/02/14 00:00 Kazançlar 2024/12/31 Yıllık Kazançlar 2024/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları Roche Holding AG 57 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Kamla Singh AlphaValue John Staszak Argus Research Company Gerhard Schwarz Baader Helvea Equity Research
Göster 54 daha fazla analist 
